The scoring is based on the following parameters: (a) very high-risk tumors (pancreatic or gastric cancer), (b) high risk tumors (lung, bladder, gynecological, lymphoma or testicular), (c) Hb level <10 mg/dL (pre-chemotherapy or use of ESA), (d) pre-chemotherapy WBC count > 11 × 109/L, (e) pre-chemotherapy platelet count ≥ 350 × 109/L, and (f) WHO performance status ≥ 2. Here, GSTM1 is linked to gastric cancer.